Clinical Trial Update: PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma [Phase 1]

View source ↗

Summary

This Phase 1 study reports on the pharmacokinetics and pharmacodynamics of XM22 in pediatric patients with Ewing sarcoma or rhabdomyosarcoma and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Rhabdomyosarcoma

Drugs mentioned

• XM22

Snippet

Sponsor: Merckle GmbH | Conditions: Ewing Family of Tumors, Rhabdomyosarcoma | Phase 1 | Status: COMPLETED